News

The other investors in PrEP Biopharm include Johnson & Johnson Innovation – JJDC and US-based angel investors. hVIVO will acquire a significant interest in PrEP Biopharm for £14m,

The three-year collaboration builds on the framework the companies have developed under a cancer metabolism partnership, which started in 2013. Merck and Selvita will contribute funding and resources

Earlier this year, Isis signed a license agreement with Bayer HealthCare for the development and commercialization of ISIS-FXIRx to prevent clotting disorders. Upon completion of ongoing activities at

Pexidartinib is an investigational novel, oral small molecule that selectively inhibits a primary growth driver of abnormal cells in the synovium that causes TGCT called colony stimulating factor-1

It is the fifth indication for Eylea, which is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. Bayer is co-developing Eylea with

These findings are a step forward in the development of targeted therapies for hard-to-treat cancers. The American Cancer Society estimates that in 2015, about 21,290 new cases of

FDA’s Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with Fast

TTIL will support a Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in

Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai. The facility will provide analytical and stability services, including analytical